key: cord-1052263-zcjm0xbi
authors: Fernández-González, Marta; Agulló, Vanesa; Padilla, Sergio; García, José Alberto; García-Abellán, Javier; Botella, Ángela; Mascarell, Paula; Ruiz-García, Montserrat; Masiá, Mar; Gutiérrez, Félix
title: Clinical performance of a standardized SARS-CoV-2 interferon-γ release assay for simple detection of T-cell responses after infection or vaccination
date: 2021-12-10
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab1021
sha: 58578b5ddbec7a2ea5767c3d33019d379d560626
doc_id: 1052263
cord_uid: zcjm0xbi

BACKGROUND: We evaluated a standardized interferon-γ (IFN-γ) release assay (IGRA) for detection of T-cell immune response after SARS-CoV-2 infection or vaccination. METHODS: This prospective study included COVID-19 patients with different severity of illness and follow-up (FU), vaccinated subjects, and healthy unvaccinated persons. SARS-CoV-2 T-cell response was measured using a specific quantitative IGRA in whole blood (Euroimmun, Germany) and TrimericS-IgG and neutralizing antibodies with validated serological platforms. Positivity of RT‐PCR or vaccination was considered as reference standard. RESULTS: Two hundred and thirty nine individuals were included (152 convalescent, 54 vaccinated and 33 uninfected unvaccinated). Overall sensitivity, specificity, positive (PPV) and negative (NPV) predictive values (95% CI) of the IGRA were 81.1% (74.9%‐86%), 90.9% (74.5%‐97.6%), 98.2% (94.5%‐99.5%), and 43.5% (31.8%‐55.9%), respectively. All vaccinated SARS-CoV-2-naïve subjects had positive IGRA at 3 months. In convalescent subjects the magnitude of IFN-γ responses and IGRA accuracy varied according to disease severity and duration of FU, with the best performance in patients with severe COVID-19 at 3-month and the worst in those with mild disease at 12-month. The greatest contribution of IGRA to serological tests was observed in patients with mild disease and long-term FU (incremental difference, 30.4%). CONCLUSION: The IGRA assessed was a reliable method of quantifying T-cell response after SARS-COV-2 infection or vaccination. In convalescent patients the sensitivity is largely dependent on disease severity and time since primary infection. The assay is more likely to add clinical value to serology in patients with mild infections.

Whilst several studies have reported decreasing circulating antibodies over time in patients recovered from COVID-19 [1] [2] [3] [4] , recent investigations indicate a robust and durable T-cell immunity, suggesting that this may be a more reliable marker of prior infection than antibody response [5] [6] [7] [8] . Therefore, to better characterize the magnitude and longevity of protective immunity against SARS-CoV-2 it may be important to measure both antibody production and T-cell response. Unlike serological assays to detect antibodies, the conventional methods of detecting T-cell immunity are complex and have not yet been standardized, requiring highly specialized facilities.

The interferon-γ (IFN-γ) release assays (IGRAs) are used in clinical laboratories to evaluate cell-mediated immune response against Mycobacterium tuberculosis or cytomegalovirus by measuring T-cell release of IFN-γ following stimulation with pathogen-specific peptides [9] [10] [11] .

Published data on the performance of the IGRAs following COVID-19 or vaccination are scarce and inconsistent [12] [13] [14] . Preliminary studies using laboratory-developed assays with different SARS-CoV-2 peptides have reported excellent sensitivity and specificity when compared with a standardized ELISpot assay [15] and have found evidence of specific T-cell response in most or all convalescent COVID-19 patients [12, 13] . However, positivity has also been reported in a significant number of healthy unexposed subjects, IgG seronegative for SARS-CoV-2, raising concerns on the specificity of these assays [14] .

The IGRAs present practical advantages over conventional methods to evaluate T-cell immune response to SARS-CoV-2. However, to determine the real performance of these tests, studies evaluating standardized methods in subjects with a broad spectrum of exposure to SARS-CoV-2 and pre-existing immunity should ideally be conducted. The aim of the present work was to evaluate the accuracy of a commercial IGRA-based SARS-CoV-2 test system to detect T-cell response (SARS-CoV-2 IGRA, Euroimmun, Lübeck, Germany) in A c c e p t e d M a n u s c r i p t 4 a diverse population of convalescent COVID-19 and vaccinated subjects, household contacts of patients with COVID-19 and healthy unexposed individuals. We also measured SARS-CoV-2 specific IgG and neutralizing antibodies titers and compared antibody and Tcell responses in the different cohorts.

This cross-sectional study was carried out at Hospital General Universitario de Elche, Spain.

The study was approved by the Institutional Ethical Committee as part of the COVID-19

Elx/Spain project (PI19/2021). Patients were selected through our centralized prospective registry of adults (≥16 years) undergoing SARS-CoV-2 testing between 15th March and 8th

July 2021. All subjects agreed to voluntarily participate in the study and gave written consent. We analysed blood samples and clinical data from the following independent cohorts of convalescent COVID-19 patients after recovery, vaccinated subjects and healthy unvaccinated persons: 1) Convalescent cohorts. We selected three cohorts of convalescent unvaccinated COVID-19 individuals, two of them comprising inpatients classified as having severe disease undergoing evaluation at 3 and 12 months after diagnosis, and a third cohort of outpatients evaluated 12 months after diagnosis. Detailed information on cohorts' characteristics and laboratory measurements is provided in Supplemental data.

Serum, EDTA plasma and whole blood specimens were obtained for measuring SARS-CoV-2-specific antibodies, neutralizing antibodies and IFN-γ release assays, respectively. Whole blood from lithium heparin tube was used for IGRA incubation within 4 hours, although the manufacturer's instructions allow up to 16 hours at room temperature (Supplemental data).

SARS-CoV-2 cellular response was measured using a specific quantitative interferon-γ release assay in whole blood following the manufacturer´s instructions (SARS-CoV-2 IGRA stimulation tube set, Euroimmun, Lübeck, Germany). Briefly, lithium heparinized blood from each patient was incubated 21h at 37ºC in the three tubes supplied. The IFN-γ concentration released in the plasma fraction obtained after centrifugation of the three tubes was then measured by ELISA (Human interferon-gamma ELISA, Euroimmun, Lübeck, Germany) with an automated instrument (Dynex DS2® ELISA system). IFN-γ response was defined as stimulated minus unstimulated. Results were interpreted as follows: IFN-γ[SARS-CoV-2] -A c c e p t e d M a n u s c r i p t 6 IFN-γ[blank]<100 mIU/mL was considered negative, 100-200 borderline, and >200 positive.

Upper limit of quantification achieved was 5000 mIU/mL.

IgG antibody serum levels against the trimeric spike protein (TrimericS-IgG) were quantified using a commercial quantitative immunoassay (LIAISON® SARS-CoV-2 TrimericS IgG assay, DiaSorin, Saluggia, Italy) in an automated platform; ≥33.8 BAU/mL was considered positive with a numeric value for quantitative measurement.

Detection of neutralizing antibodies against SARS-CoV-2 (NAb) was performed in an automated instrument (Dynex DS2® ELISA system) by means of a surrogate neutralizing antibody test (SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Germany). Results were interpreted as inhibition percentage (%IH): <20 was considered negative, ≥20 to <35 borderline, and ≥35 positive.

Continuous variables are expressed as median ±25th and 75th percentiles (Q1-Q3), and categorical variables as percentages. The percent agreement (positive, negative and overall) for SARS-CoV-2 IGRA was calculated using the TrimericS-IgG and NAb assaysas reference standard. Borderline values for NAb and IGRA were considered negatives for these calculations. We determined IGRA sensitivity, specificity and positive (PPV) and negative 

A total of 239 individuals were recruited into the study, including 152 convalescent patients, 54 vaccinated and 33 uninfected and unvaccinated healthy donors. Flowchart of study subjects is shown in Figure 1 . The clinical and demographic characteristics of each study group are shown in Table 1 . Median (Q1-Q3) age was 60 (47-70) years, 130 (54.4%) were male, and 98% self-identified as white. 15.7%-40.6%), respectively ( Table 2) .

Levels of TrimericS-IgG correlated significantly with the magnitude of the SARS-CoV-2specific T-cell response measured by the IGRA (Figure 2 ). Table 3 illustrates the concordance between IGRA and SARS-CoV-2 antibodies in the convalescent and vaccinated cohorts. Overall agreement between the IGRA and both TrimericS-IgG and neutralizing antibodies was good, in particular between IGRA and TrimericS-IgG, with the lowest values found for negative percent agreement in convalescent cohorts.

Among all convalescent subjects, the median (Q1-Q3) age was 60 (48-70) years and 88 

The group of vaccinated SARS-CoV-2-naïve subjects comprised health care workers that were younger and with a higher number of females compared with those vaccinated after previous COVID-19 (Table 1) SARS-CoV-2-infected subjects receiving one or two vaccine doses showed strong humoral and cellular responses with median TrimericS-IgG and IFN-γ concentrations higher than those seen in vaccinated SARS-CoV-2-naïve individuals ( Figure 3C ). Of note, these subjects were tested much earlier post-vaccination. The magnitude of both antibody and Tcell responses observed in these groups were well above the observed in any of the unvaccinated convalescent cohorts (Table 1) . Interestingly, one subject receiving one and another receiving two vaccine doses after prior COVID-19 had not developed T-cell response by the IGRA assay. when adding borderline IGRA results to serological tests. In contrast, we did not find a significant contribution of IGRA in the vaccinated cohorts ( Figure S1 ).

The commercial SARS-CoV-2 IGRA used in this study accurately distinguished significantly lower compared with patients tested at 3 months. In contrast, more than half of patients with mild disease did not maintain IFN-γ responses nor anti-spike IgG antibodies at 12 months after diagnosis, suggesting weaker long-term protection against SARS-CoV-2 following mild primary infections. This finding is coherent with the IFN-γ decline observed in a small cohort of outpatients tested with IGRA on days 17 and 31 post-RT-PCR positivity [13] , and with the rapid decay of anti-SARS-CoV-2 antibodies described in persons with mild COVID-19 [1] .

As expected, we found that SARS-CoV-2-naïve subjects had positive responses in the IGRA assay after vaccination, although the IFN-γ levels were significantly lower than those seen in convalescent patients with severe COVID-19 tested at the same timepoint, that suggesting that natural T-cell immunity after severe infection may be stronger compared to vaccination.

Noteworthy was the strong T-cell response observed following either one or two vaccine doses in previously infected subjects. This observation matches with previous studies demonstrating robust T-cell responses in previously infected individuals after one vaccine dose, equivalent to naïve individuals receiving two doses [23] . cross-reactive T-cell recognition between circulating "common cold" coronaviruses and SARS-CoV-2 [14, 24] , and, therefore, questioning their role as a potential diagnostic tool for assessing protective immunity against SARS-CoV-2. Interestingly, SARS-CoV-2-specific Tcells have been found in some convalescent individuals in the absence of seroconversion [6, 8] and this may be more likely to occur in mild or asymptomatic infection [8, 25, 26] . Thus, the three positive IGRA results of our study, in household contacts, may indeed reflect A c c e p t e d M a n u s c r i p t 13 asymptomatic SARS-CoV-2 exposure and protective T-cell mediated immunity. If those were true-positive cases, the specificity of the assay would approach 100%. Nonetheless, either false-positive results or cross-reactivity with seasonal coronaviruses cannot be rule out.

To examine the potential contribution of the IGRA to conventional serological testing to assess immunity in clinical practice, we compared the presence of SARS-CoV-2 specific IgG and neutralizing antibodies with IFN-γ responses in patients recovered from the disease and vaccinated subjects. Overall, the IGRA increased only modestly the detection of immunity, but the contribution was substantial in convalescent patients with mild disease, where IGRA augmented the yield of serology by 13% (30% when including borderline values).

The study was limited by the small sample size in some subgroups limiting the precision of the estimations, and by the lack of demographic matching between the different cohorts with unbalanced sex distribution, reflecting the selection bias towards health care workers participating voluntarily in vaccinated cohorts. Unfortunately, the cross-sectional study design did not allow us evaluating the clinical impact of implementing IGRA to assess immunity memory after SARS-CoV-2 infection or vaccination nor the value of the test for predicting future SARS-CoV-2 infection.

This study has several notable strengths, including the utilization of standardized, high throughput IGRA and validated serological platforms to accurately measure antibody response in a diverse cohort of individuals with varying degrees of illness severity and follow-up, along with exposed and unexposed controls. To our knowledge this is the largest study to date to evaluate the performance of an easy-to-use assay for detection of cellular immune response in a clinical setting.

In conclusion, the commercial kit of whole blood SARS-CoV-2 IGRA assessed in this investigation is a simple and reliable method of quantifying T-cell response in convalescents and vaccinated subjects. In convalescent patients the sensitivity is largely dependent on the Carlos III -Subdirección General de Evaluación y Fondo Europeo de Desarrollo Regional (grants PI16/01740, PI18/01861, CM19/00160, CM20/00066, COV20/00005). 

Antibodies in Persons with Mild Covid-19

Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

Dynamics of Neutralizing Antibody titers in the months after Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Contribution of interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test

Gamma interferon release assays for detection of Mycobacterium tuberculosis infection

Interferon-γ Release Assay for Cytomegalovirus (IGRA-CMV) for Risk Stratification of Posttransplant CMV Infection: Is It Time to Apply IGRA-CMV in Routine Clinical Practice?

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients

Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response

Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay

SARS -CoV-2 T-cell immunity to variants of concern following vaccination

The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role

Evolution of antibody immunity to SARS-CoV-2

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation

T-Cell and Antibody Responses to First BNT162b2

Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicenter, Prospective, Observational Cohort Study

Targets of T Cell Responses to SARS-CoV-2

Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

Healthy unvaccinated cohorts (N=33) were considered as reference standard for negative results. # Subanalysis excluding household contacts of COVID-19 (All, n=220)

Subanalysis considering IGRA borderline values (≥100 mIU/mL) as positive

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 21 Table 2 . Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of the IFN-γ release assay (IGRA).